Amplia Therapeutics Ltd.ASX: ATX

Ethics Approval for Amplia's ACCENT-Mini Trial

· Issued by Amplia Therapeutics Ltd. via ASX

Filed with ASX · · 2 pages · English

Summary by 6ix AI

Amplia Therapeutics Ltd. has received ethics approval for its ACCENT-Mini trial, which will evaluate the combination of narmafotinib with gemcitabine and Abraxane in metastatic pancreatic cancer. This trial builds on previous encouraging results from the ACCENT trial, which showed improved outcomes compared to chemotherapy alone. Safety and pharmacokinetic data from the ACCENT-Mini trial are expected to support a future FDA protocol submission. The trial is a significant step in Amplia's strategy to enhance treatment options for difficult-to-treat cancers.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

19 NOVEMBER 2026 ASX RELEASE ETHICS APPROVAL FOR AMPLIA’S ACCENT-MINI TRIAL HIGHLIGHTS • Ethics approval received for ACCENT-Mini, evaluating daily-dosed narmafotinib with gemcitabine and Abraxane in metastatic pancreatic cancer • The trial builds on encouraging ACCENT results, including a...

Amplia Therapeutics Ltd. on 6ix

Earlier from Amplia Therapeutics

All Amplia Therapeutics news releases